Crown Laboratories to acquire Revance Therapeutics for $924m.

Crown Laboratories, a skincare company, agreed to acquire Revance Therapeutics, a biotechnology company, for $924m. "This is a significant step forward in Crown's vision to become a fully integrated global aesthetics and skincare company, bringing innovative solutions to physicians, patients and consumers in the incredibly dynamic aesthetics and skincare market. Revance has an impressive track record in developing innovative aesthetics offerings that will complement Crown's innovative line of skincare products. As a combined company, we have the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and we will be committed to investing in education, training, and practice support for aesthetics providers across the United States," Jeff Bedard, Crown Laboratories Founder and CEO.